Grenoble, 1st Septembre 2015 – Kayentis, French software provider specialized in solutions for clinical pharmaceutical trials, has just chosen SFR Business Team for its M2M roaming in close to 250 countries.
Kayentis has been a leading name in solutions for clinical trials for 10 years. 18 months ago, in addition to its emblematic digital pen device, the company launched a solution enabling patient data to be entered by tablet.
In order to implement its solutions in the international market, Kayentis wished to approach a major player in the telecoms sector and thus chose SFR Business Team. The partnership agreement between the two companies authorises M2M roaming in close to 250 countries.
This solution guarantees permanent connectivity between the clinic investigation centres, where the data is collected, the Kayentis database servers and the portal provided for its customers.
It has already been implemented in more than 40 countries, via two eCOA projects (eClinical Outcome Assessment) for phase III clinical studies, linked with one of the five largest pharmaceutical laboratories in the world.
Working with SFR Business Team has enabled Kayentis to lean on one of the leading names in MtoM solutions worldwide and strengthen the brand’s ambitious plans for development.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.